|Description||DPC-681, sulfonamide derivatives, is an extremely potent and selective inhibitor of HIV protease. IC90s: wild-type HIV-1=4-40 nM|
|Synonyms||DPC 681; DPC-681; DPC681; DPH 153893; DPH-153893; DPH153893; (2R)-N-(2-aminoacetyl)-2-[[(2S)-4-[(3-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-[(3-fluorophenyl)methyl]amino]-3,3-dimethylbutanamide284661-68-3AM021737N-((3-Fluorophenyl)methyl)glycyl-N-((1S,2R)-3-(((3-aminophenyl)sulfo|
|Solubility||Soluble in DMSO|
|Storage||Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -27℃ for long term (months to years).|
|Shelf Life||2 years|
CC-3052, a thalidomide analogue, reduces persistent activation of the TNF-α system in HIV without markedly impairing neutrophil viability.
BMS-186318 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb.
BMS-187071 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb.
MK-8718 has been found to be a HIV protease inhibitor and could be studied in HIV research.
CI-1029 is a nonpeptidic inhibitor of HIV protease, potenat against mutant HIV protease and resistant HIV strains.
CGP-75355 is an HIV Protease inhibitor (EC50= 0.7 nM).
The hydrochloride salt form of MK-8718 which has been found to be a HIV protease inhibitor and could be studied in HIV research.
A potent inhibitor of HIV-l protease (IC50= 1 nM)